American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. - Wikidata - wikimedia - TriplyDB

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.

http://www.wikidata.org/entity/Q34803386

about

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies Bisphosphonates: mechanism of action and role in clinical practice Problems monitoring response in multiple myeloma Medication-related osteonecrosis of the jaw: Clinical and practical guidelines Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report Use of Ultrasonic Bone Surgery (Piezosurgery) to Surgically Treat Bisphosphonate-Related Osteonecrosis of the Jaws (BRONJ). A Case Series Report with at Least 1 Year of Follow-Up.Efficacy and tolerability of medical ozone gas insufflations in patients with osteonecrosis of the jaw treated with bisphosphonates-Preliminary data: Medical ozone gas insufflation in treating ONJ lesions Statins Are Associated With Reduced Mortality in Multiple Myeloma.Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN Risk Assessment of BRONJ in Oncologic Patients Treated with Bisphosphonates: Follow-Up to 18 Months Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis.Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.Zoledronic Acid may reduce intraoperative bleeding in spinal tumors: a prospective cohort study Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice.Novel therapeutic approaches for multiple myeloma.RANK/RANKL/OPG signaling pathways in necrotic jaw bone from bisphosphonate-treated subjects Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw.How concerns for bisphosphonate-induced osteonecrosis of the jaw affect clinical practice among dentists: a study from the South Texas Oral Health Network.New insights into the pathophysiology and management of bone disease in multiple myeloma.Bisphosphonate therapy in the oncology setting.Bisphosphonate-associated osteonecrosis of the jaw: the rheumatologist's role.Effect of the cumulative dose of zoledronic acid on the pathogenesis of osteonecrosis of the jaws.Time associated with intravenous zoledronic acid administration in patients with breast or prostate cancer and bone metastasis Pharmaceutical inhibition of glycogen synthetase kinase-3β reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model Bisphosphonate therapy in multiple myeloma in preventing vertebral collapses: preliminary report.Targeting cells of the myeloid lineage attenuates pain and disease progression in a prostate model of bone cancer Myeloma bone disease: pathophysiology and management.Bisphosphonate induced osteonecrosis of jaw in breast cancer patients: A systematic review Current therapeutic uses of lenalidomide in multiple myeloma.Common complaints, difficult diagnosis: multiple myeloma.Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists.A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer.Acute kidney injury and bisphosphonate use in cancer: a report from the research on adverse drug events and reports (RADAR) project Decreasing frequency of osteonecrosis of the jaw in cancer and myeloma patients treated with bisphosphonates: the experience of the oncology network of piedmont and aosta valley (north-Western Italy)Zoledronic acid in the management of metastatic bone disease.Bisphosphonate-induced osteonecrosis of the jaw.Associations between Systemic Markers of Bone Turnover or Bone Mineral Density and Anti-Resorptive Agent-Related Osteonecrosis of the Jaw in Patients Treated with Anti-Resorptive Agents.Bisphosphonate-associated osteonecrosis of the jaw The safety of zoledronic acid.

P2860

Q21245492-2F7B5264-41D4-42EC-B3DC-AFC863537800 Q24644708-F73C9A04-FB1B-496B-80DC-AE238F57EA9A Q24676888-F3E1D005-C91A-4972-9796-BD919FE5EE2F Q26749965-75127DB3-CEDE-449A-8F2D-0C09BF80843D Q28275303-FF43E9C6-B50B-4938-8AF7-5B61B2332E51 Q30449286-772CD42A-D81E-4354-96EB-981727C5EF60 Q31048683-741EF60E-B990-4D43-82A9-3E6DFE89A958 Q33816591-A0D2A860-E81E-4342-8A9B-704EF87D4370 Q34164223-D8355D3E-60B0-4811-99AC-F1EB3E393D09 Q34204571-AB94CF3B-15E1-4070-8393-639646BB8939 Q34381979-F243BB7F-A012-45DF-AE6F-470A67C0E102 Q34960635-C8480755-D200-4926-BB26-05460E76C8A1 Q35050733-79CF69B1-E496-4DEB-94FD-DC9A746CB210 Q35157851-64989AFE-8C09-443F-B082-C52776415624 Q35170935-187AE987-09F3-449B-A655-BB6CA7CB94B8 Q35228787-826CFDF4-9733-45FB-8B16-FE60F870AFC5 Q35583788-018A8D2D-1A87-4B4C-8A03-493ED12293F7 Q35584343-56A1FE09-AE15-48FD-85B2-95A66F5EA521 Q35590055-A3DF1FF7-5039-4535-896F-17D9504D5647 Q35591086-EF7AAED7-98ED-4AEE-B8CD-6BFB0BC198E5 Q35602668-0EF9F4C9-01E0-45A3-ACE0-247294D72A5B Q35605709-6A19BF16-09D2-4E97-971E-C3A5ACA5212E Q35803713-D5DFB739-9644-4952-BFD8-2CC04301E496 Q35832155-E4185C6E-E100-4159-A9C9-A4AD1B99FA51 Q35868347-9F141B67-00D4-49FA-A639-86E7C6518F8D Q35886257-59625675-9511-4C13-A483-8AFA34575467 Q35985440-247F17C6-7714-484A-97C2-23BB196A366E Q36146493-0F4C5CCD-BD31-4F47-9A9C-46F138683F65 Q36181162-D9410521-A079-441A-89EA-60747CC02756 Q36376450-2F66D056-F7B1-48CC-9B99-FD90834A9E25 Q36471721-BA7EB51B-69A1-4992-B2F3-8574D2610ADC Q36491413-C2D2E5DE-B716-4A4C-81EF-FD19FEF3FD19 Q36491537-56D9F282-010C-4A06-B000-06F62D0A8FB5 Q36678173-B37159CC-DCAA-4367-A222-43B49D25624A Q36691952-4C970661-DEDF-4D34-AD9E-F2745DD76E35 Q36708315-B5BBD1A7-6ECE-4288-A8AE-59A8BFB3DA80 Q36735192-C1507331-65D9-49F2-A6DB-E1AA4C705536 Q36753894-C32D53CB-DBB2-452A-A7D8-A7F0E26C6536 Q36767037-DB7ACFD7-EE09-4C84-A4E9-BC1C0C885205 Q36811542-9E216633-8119-4D3D-A3D8-12E68CA32FD8

P2860

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.

http://www.wikidata.org/entity/Q34803386

description

2002 nî lūn-bûn

@nan

2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

American Society of Clinical O ...... sphonates in multiple myeloma.

@ast

American Society of Clinical O ...... sphonates in multiple myeloma.

@en

American Society of Clinical O ...... sphonates in multiple myeloma.

@nl

type

label

American Society of Clinical O ...... sphonates in multiple myeloma.

@ast

American Society of Clinical O ...... sphonates in multiple myeloma.

@en

American Society of Clinical O ...... sphonates in multiple myeloma.

@nl

prefLabel

American Society of Clinical O ...... sphonates in multiple myeloma.

@ast

American Society of Clinical O ...... sphonates in multiple myeloma.

@en

American Society of Clinical O ...... sphonates in multiple myeloma.

@nl

P1433

Q34803386-1F96F3D5-1E76-40CE-9AC5-6FB5CAF8DB8D

P1476

Q34803386-3597E873-8488-4F41-82E7-6B4383EE5E5E

P2093

Q34803386-2BBB3F88-3532-41CD-B5B6-C7A9C7032341

Q34803386-4426F0A3-9A43-4FC4-945B-DA8E6F370D19

Q34803386-55258C65-D3D7-4824-AB33-F0A46B227820

Q34803386-57E82918-535C-4BEF-A9C9-CC55223B63E4

Q34803386-58DE11EA-1507-4337-8E82-3EFC30EB686E

Q34803386-B928F735-46DD-4D68-A372-87CF49EA7EA0

Q34803386-DFCCB225-A88C-4633-81BC-C9C87E34E05D

P304

Q34803386-97E1F27A-7A70-4D50-9E0E-CF263CB65ED4

P31

Q34803386-7062CE74-DB61-4C12-B64F-0374615F6283

P356

Q34803386-E973262F-D19C-40AF-8B9F-D839E14CFFA6

P407

Q34803386-D0B221A9-9506-414F-8649-FAD0E290FEDB

P433

Q34803386-DB129BCF-B3FD-48FA-B665-0050A59A894D

P478

Q34803386-5CBEF694-E539-479F-91C9-004377D9F57C

P50

Q34803386-5A5F0B4C-7A7A-43A1-AD8F-E4D0A27259EE

P577

Q34803386-FA9A8EBF-6132-4245-B22F-9B226F4F2783

P698

Q34803386-E3D6B6C2-467F-4F26-80BB-CB6C30B24C09

P356

JCO.2002.06.037

P1433

Journal of Clinical Oncology

P1476

American Society of Clinical O ...... sphonates in multiple myeloma.

@en

P2093

Allan Lipton

http://www.w3.org/2001/XMLSchema#string

American Society of Clinical Oncology Bisphosphonates Expert Panel

http://www.w3.org/2001/XMLSchema#string

Bruce E Hillner

http://www.w3.org/2001/XMLSchema#string

Gary C Yee

http://www.w3.org/2001/XMLSchema#string

J Sybil Biermann

http://www.w3.org/2001/XMLSchema#string

James R Berenson

http://www.w3.org/2001/XMLSchema#string

Ken Anderson

http://www.w3.org/2001/XMLSchema#string

P304

3719-3736

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2002.06.037

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12202673

http://www.w3.org/2001/XMLSchema#string